Nothing Special   »   [go: up one dir, main page]

ATE322258T1 - Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren - Google Patents

Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren

Info

Publication number
ATE322258T1
ATE322258T1 AT01926875T AT01926875T ATE322258T1 AT E322258 T1 ATE322258 T1 AT E322258T1 AT 01926875 T AT01926875 T AT 01926875T AT 01926875 T AT01926875 T AT 01926875T AT E322258 T1 ATE322258 T1 AT E322258T1
Authority
AT
Austria
Prior art keywords
methods
compositions
modulating
alpha
activity
Prior art date
Application number
AT01926875T
Other languages
English (en)
Inventor
Ken Chow
Daniel W Gil
Wenkui Ken Fang
Michael E Garst
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE322258T1 publication Critical patent/ATE322258T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT01926875T 2000-04-13 2001-04-11 Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren ATE322258T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54831500A 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
ATE322258T1 true ATE322258T1 (de) 2006-04-15

Family

ID=24188299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926875T ATE322258T1 (de) 2000-04-13 2001-04-11 Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren

Country Status (11)

Country Link
US (1) US6545182B2 (de)
EP (1) EP1280524B1 (de)
JP (1) JP2003530429A (de)
AT (1) ATE322258T1 (de)
AU (2) AU5338301A (de)
CA (1) CA2405796C (de)
DE (1) DE60118544T2 (de)
ES (1) ES2260216T3 (de)
HK (1) HK1051005A1 (de)
TW (1) TWI278446B (de)
WO (1) WO2001078702A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DK1339438T3 (da) * 2000-11-29 2006-02-13 Allergan Inc Forebyggelse af transplantatafvisning i ojet
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
NZ535165A (en) * 2002-02-13 2006-08-31 Vitreo Retinal Technologies In Treatment of ophthalmic disorders using urea and urea derivatives
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
AU2003299560A1 (en) * 2002-11-13 2004-06-03 Sepracor, Inc. Compositions and methods for treating or preventing hearing impairment
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1791832A1 (de) 2004-09-24 2007-06-06 Allergan, Inc. 4-(heteroarylmethyl und substituiertes heteroarylmethyl)imidazol-2-thione, die als alpha2-adrenerge agonisten wirken
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US7709507B2 (en) * 2006-05-17 2010-05-04 Allergan, Inc. Therapeutic fluoroethyl ureas
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2007337097A1 (en) 2006-12-22 2008-07-03 Allergan, Inc. Alpha-2B adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
WO2009009278A1 (en) * 2007-07-06 2009-01-15 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US9034910B2 (en) * 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
AU2010289703A1 (en) 2009-08-26 2012-04-12 Allergan, Inc. Method of treating compulsive disorders with alpha-2B adrenergic receptor agonists
SI2605771T1 (sl) 2010-08-16 2018-09-28 Allergan, Inc. Metoda aktivacije regulatornih celic t z agonisti adrenergičnih receptorjev alfa-2b

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562391A (en) * 1969-06-17 1971-02-09 American Cyanamid Co Method of suppressing inflammation in mammals
US3969532A (en) * 1974-02-01 1976-07-13 The Dow Chemical Company 1-Aryl-3-(2-hydroxyethyl) thioureas for treating depression
US3950538A (en) * 1974-03-18 1976-04-13 The Dow Chemical Company Anti-inflammatory methods utilizing certain thioureas
US4009284A (en) * 1975-02-26 1977-02-22 Rohm And Haas Company Gastrointestinally active thioureas
SU795462A3 (ru) * 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US4460602A (en) * 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
GB8715357D0 (en) * 1987-06-30 1987-08-05 Sandoz Inst For Medical Resear Organic compounds
US4988688A (en) * 1989-08-02 1991-01-29 Warner-Lambert Company 4-(N-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
HU210683B (en) * 1990-06-18 1995-06-28 Sandoz Ag Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Also Published As

Publication number Publication date
ES2260216T3 (es) 2006-11-01
TWI278446B (en) 2007-04-11
JP2003530429A (ja) 2003-10-14
HK1051005A1 (en) 2003-07-18
US6545182B2 (en) 2003-04-08
EP1280524B1 (de) 2006-04-05
US20020058839A1 (en) 2002-05-16
CA2405796A1 (en) 2001-10-25
WO2001078702A3 (en) 2002-03-21
CA2405796C (en) 2010-01-05
DE60118544D1 (de) 2006-05-18
DE60118544T2 (de) 2007-02-08
AU5338301A (en) 2001-10-30
WO2001078702A2 (en) 2001-10-25
EP1280524A2 (de) 2003-02-05
AU2001253383B2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
MY140767A (en) Compounds, methods and compositions
WO2003103575A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
ATE408601T1 (de) Fredericamycin-derivate
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
MY140169A (en) Compounds, compositions, and methods
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60237003D1 (de) Verwendung von 3-positions-cyclosporin-derivaten für haarwachstum
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties